Aldeyra Therapeutics, Inc. (FRA:137)
Germany · Delayed Price · Currency is EUR 4.688
+0.032 (0.69%)
At close: Nov 28, 2025
Aldeyra Therapeutics Employees
Aldeyra Therapeutics had 9 employees as of December 31, 2024. The number of employees decreased by 1 or -10.00% compared to the previous year.
Employees
9
Change (1Y)
-1
Growth (1Y)
-10.00%
Revenue / Employee
n/a
Profits / Employee
€4,601,772
Market Cap
271.18M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | -1 | -10.00% |
| Dec 31, 2023 | 10 | -5 | -33.33% |
| Dec 31, 2022 | 15 | 3 | 25.00% |
| Dec 31, 2021 | 12 | 1 | 9.09% |
| Dec 31, 2020 | 11 | -9 | -45.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 318,000 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 103,000 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Aldeyra Therapeutics News
- 15 days ago - Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye - Slideshow - Seeking Alpha
- 18 days ago - Aldeyra Therapeutics, Inc. (ALDX) Discusses Expansion of RASP Platform Into CNS Diseases and Update on Reproxalap for Dry Eye Transcript - Seeking Alpha
- 18 days ago - Aldeyra (ALDX) Expands RASP Platform to Target Neuroinflammatory Diseases - GuruFocus
- 18 days ago - Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast - Business Wire
- 20 days ago - Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - Business Wire
- 22 days ago - ALDX: BTIG Reiterates Buy Rating with Price Target Maintained at $9.00 | ALDX Stock News - GuruFocus
- 25 days ago - Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET - Business Wire
- 4 weeks ago - Aldeyra (ALDX) Advances Drug Pipeline with Positive Trial Results - GuruFocus